Sit Less, Interact and Move More (SLIMM) 2 Study

Who is this study for? Patients with chronic kidney disease
What treatments are being studied? SLIMM+Guided Resistance Training+Semaglutide
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Behavioral, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: f
View:

• Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2

• Able to perform resistance training

• Access to compatible smartphone or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop

Locations
United States
California
Stanford University
RECRUITING
Stanford
Utah
University of Utah
RECRUITING
Salt Lake City
Contact Information
Primary
Amara Sarwal, M.D.
Amara.Sarwal@hsc.utah.edu
801-585-9815
Time Frame
Start Date: 2021-12-01
Estimated Completion Date: 2027-03-31
Participants
Target number of participants: 156
Treatments
Placebo_comparator: SLIMM + Standard RT + Placebo
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, standard-of-care resistance training and oral placebo
Active_comparator: SLIMM + Guided RT + Placebo
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral placebo
Experimental: SLIMM + Guided RT + Semaglutide
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral semaglutide
Related Therapeutic Areas
Sponsors
Leads: Srinvasan Beddhu
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Stanford University

This content was sourced from clinicaltrials.gov